A Phase 3 Study Assessing the Addition of High-Dose, Targeted Radiation to the Usual Treatment for Inoperable Non-Small Cell Lung Cancer

In the U.S.

Full Title

Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally-Advanced Non-Small Cell Lung Cancer (NRG LU008) (CIRB)

Purpose

Researchers want to see if giving additional radiation therapy to standard treatment helps people with lung cancer to live longer. The people in this study have non-small cell lung cancer (NSCLC) that cannot be removed with surgery (inoperable cancer). The standard treatment includes image-guided radiation therapy (IGRT), chemotherapy, and immunotherapy with durvalumab.

IGRT uses a computer to make a picture of the tumor and more accurately guide radiation beams (invisible energy waves). The chemotherapy in this study includes 5 anti-cancer drugs. Durvalumab immunotherapy boosts the power of the immune system to fight cancer. These medications are given intravenously (by vein).

The additional radiation therapy to be assessed is called stereotactic body radiation therapy (SBRT). SBRT uses special equipment to deliver radiation to tumors with very high precision. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. If you join this study, you will be randomly assigned to receive the standard NSCLC treatment with or without SBRT.